# Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD)

consortiapedia.fastercures.org/consortia/safeguard/

## Research Areas

- Basic Research
- Data-Sharing Enabler
- Product Development
  - Data

## At a Glance

- Status: **Active Consortium**
- Year Launched: **2011**
- Initiating Organization: **European Commission Seventh Framework Programme (FP7)**
- Initiator Type: **Government**
- Location: **Europe**

## Abstract

The primary aim of the Safety Evaluation of Adverse Reactions in Diabetes (SAFEGUARD) consortium is to assess and further quantify and understand the cardio/cerebrovascular and pancreatic safety of blood glucose–lowering agents, in particular the thiazolidinediones (TZDs) and the novel incretin-based drugs and amylin analogs in Type 2 diabetes mellitus (T2DM) patients. The SAFEGUARD consortium is formed by a multidisciplinary group including diabetes experts, clinicians, pharmacologists, pharmacovigilance experts, statisticians, and pharmacoepidemiologists, and it will capitalize on knowledge generated in other European Union (EU)–funded projects to create a harmonized data platform. This platform will allow for the largest scale studies on T2DM drugs developed so far as well as for the implementation of new epidemiological studies.

## Mission

The SAFEGUARD studies include the following:

## Consortium History

Oct. 1, 2011: Project started
Sept. 30, 2015: Project ended

## Structure & Governance

SAFEGUARD's work is divided into the following Work Packages (WPs):
WP1 and WP2 provide scientific leadership and operational management to project research. WP3 to WP7 are the main knowledge-generating and scientific work packages, and each deals with different data substrates:

## Financing

The funding scheme is through the European Union's Seventh Framework Programme (small or medium-scale focused research project). The project cost is €3.9 million. Funding is €3.0 million.

## Links/Social Media Feed

Homepage http://www.safeguard-diabetes.org/

## Points of Contact

Scientific Coordinator:
Miriam Sturkenboom
Department of Medical Informatics
Erasmus University Medical Center
email: m.sturkenboom@erasmusmc.nl

Project Manager:
Mireia Manent
Synapse Research Management Partners S.L.

email: mmanent@synapse-managers.com

Contact: info@safeguard-diabetes.eu

## Sponsors & Partners

Agencia Espanola de Medicamentos y Productos Sanitarios
BIPS Institut fur Epidemiologie und Praventionsforschung GmbhH
Consorzio Mario Negri Sud
Drug Safety Research Trust
Erasmus Medical Center
Fondaziones Scientifica SIMG-ONLUS
PHARMO Institute N.V.
RTI Health Solutions
Stichting VU-VUMC
Synapse Research Management Partners
The Brigham and Women's Hospital, Harvard Medical School
Universitaet Bremen
University of Bath
University of Milano - Bicocca
Univerzita Karlova v Praze

Updated: **04/15/2016**